Skip to main content
. 2016 May 27;30(8):1084–1090. doi: 10.1038/eye.2016.96

Figure 2.

Figure 2

Comparison of functional and anatomical outcomes between the two groups. (a) The mean BCVA (logMAR) during follow-up periods between the two groups. At 1, 3 and 6 months after the initial injection, there was a significant improvement from baseline within this group (IVB; P=0.018, P=0.041, P=0.014, IVB/STA; P=0.012, P=0.002, P=0.001). (b) The mean change in BCVA (logMAR) from baseline during follow-up periods between the two groups. There was a no significant difference at any time point between two groups. (c) The Mean central macular thickness (CMT) during follow-up periods between the two groups. At 1, 3 and 6 months after the initial injection, there was a significant improvement from baseline within this group (IVB and IVB/STA; P<0.001, P<0.001, P<0.001). There was a significant difference between the two groups at 1 month (P=0.015).